These regulatory documents describe how the safety of a medicinal product will be managed and monitored post-authorisation. These plans are essential for preventing and minimising risks in patients and evaluating the effectiveness of the measures taken. As new information becomes available throughout the drug’s lifetime, RMPs/REMS are continually modified and updated. We will adopt a strategic approach in order to provide clear, robust risk documents that anticipate the expectations of regulators authorities.